Connect with us

Technology

Fusion Biopsy Market is expected to generate a revenue of USD 1448.15 Million by 2032, Globally, at 8.9% CAGR: Verified Market Research®

Published

2 years ago

on

Verified Market Research®, a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the Fusion Biopsy Market. This in-depth study provides industry leaders, medical device manufacturers, healthcare providers, and investors with critical insights into the evolving landscape of fusion biopsy technologies.

LEWES, Del., March 5, 2025 /PRNewswire/ — The Global Fusion Biopsy Market Size is projected to grow at a CAGR of 8.9% from 2025 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 732.13 Million in 2024 and is expected to reach USD 1448.15 Million by the end of the forecast period.

The Fusion Biopsy Market is witnessing rapid growth, driven by increasing adoption of precision diagnostic techniques for prostate cancer and other malignancies. Fusion biopsy, which combines MRI and ultrasound imaging, has emerged as a game-changer in early cancer detection and treatment planning. The report delves into market dynamics, including technological advancements, regulatory updates, and competitive strategies shaping the industry.

Key Highlights of the Market Report:

Market Size & Growth Projections – Detailed analysis of the current market valuation, CAGR, and forecasted growth potential through 2032.Technological Innovations – Insights into the latest advancements in MRI-ultrasound fusion biopsy techniques, AI-powered imaging, and real-time navigation systems.Competitive Landscape – Profiles of key players, including mergers, acquisitions, and strategic partnerships that are redefining the market.Regional Analysis – Market trends and investment opportunities across North America, Europe, Asia-Pacific, and other emerging regions.End-User Insights – Adoption trends across hospitals, diagnostic centers, and research institutions.

Why This Report Matters?

With the increasing burden of cancer cases worldwide, precision diagnostics are more crucial than ever. Industry stakeholders seeking data-driven insights on investment opportunities, emerging technologies, and strategic positioning will find this report invaluable.

For more information or to purchase the report, please contact us at: https://www.verifiedmarketresearch.com/download-sample?rid=480739

Browse in-depth TOC on “Global Fusion Biopsy Market Size“

202 – Pages
126 – Tables
37 – Figures

Report Scope

REPORT ATTRIBUTES

DETAILS

STUDY PERIOD

2021-2032

BASE YEAR

2024

FORECAST PERIOD

2025-2032

HISTORICAL PERIOD

2021-2023

UNIT

Value (USD Million)

KEY COMPANIES PROFILED

Eigen, Koninklijke Philips N.V., Hitachi Ltd., Focal Healthcare, MedCom, ESAOTE SPA, KOELIS, BK Medical Holding Company Inc., Biobot Surgical Pte Ltd, Exact Imaging, and UC-Care Medical Systems Ltd.

SEGMENTS COVERED

Biopsy Route, Product, End User, And Geography.

CUSTOMIZATION SCOPE

Free report customization (equivalent to up to 4 analyst working days) with purchase. Addition or alteration to country, regional & segment scope

Global Fusion Biopsy Market Overview

Key Market Drivers

Rising Prevalence of Prostate Cancer and Need for Early Diagnosis: The rising global prevalence of prostate cancer significantly propels the Fusion Biopsy Market. Conventional biopsy techniques frequently result in false negatives, postponing essential therapies. Fusion biopsy, integrating MRI and ultrasound, improves precision and early diagnosis, establishing it as the preferred method for urologists and oncologists. As healthcare providers emphasize precision diagnostics, the need for fusion biopsy systems is anticipated to increase, propelling market expansion.

Technological Advancements in Imaging and AI Integration: The advancement of MRI-ultrasound fusion biopsy technology, enhanced by artificial intelligence and real-time imaging, is revolutionizing cancer diagnoses. AI-driven automation enhances lesion diagnosis and biopsy targeting, minimizing mistakes and increasing productivity. The Fusion Biopsy Market is experiencing swift adoption in hospitals and diagnostic centers as manufacturers invest in advanced imaging systems. Organizations utilizing AI-driven biopsy advancements will acquire a significant competitive advantage.

Increasing Investments and Favorable Regulatory Approvals: Government entities and private investors are significantly financing precision diagnostic solutions, hence generating development prospects in the Fusion Biopsy Market. Beneficial FDA approvals and efficient regulatory frameworks are accelerating product introductions and promoting innovation. Increasing healthcare expenditures and reimbursement policies favoring sophisticated biopsy treatments are enhancing market penetration. Enterprises that use regulatory changes will experience substantial revenue growth.

To Purchase a Comprehensive Report Analysis: https://www.verifiedmarketresearch.com/select-licence?rid=480739

Market Restraints Hindering the Market Growth

High Cost of Fusion Biopsy Systems and Procedures: Notwithstanding its clinical benefits, the Fusion Biopsy Market encounters obstacles owing to the substantial expense of MRI-ultrasound fusion biopsy devices. Advanced imaging technology and AI-driven biopsy instruments necessitate significant investment, constraining adoption by small and medium-sized healthcare institutions. Cost-sensitive markets, especially in emerging areas, face challenges with affordability, hindering widespread implementation and impeding market growth.

Limited Access to Skilled Radiologists and Urologists: The efficacy of fusion biopsy is contingent upon the proficiency of radiologists and urologists skilled in MRI-ultrasound-guided techniques. A deficiency of trained professionals, particularly in emerging regions, is constraining market expansion. Healthcare facilities encounter difficulties in adopting and optimizing fusion biopsy technologies without enough training. Mitigating this deficiency through educational and certification initiatives is essential for fostering enduring adoption and maintaining growth in the Fusion Biopsy Market.

Stringent Regulatory Requirements and Approval Delays: Despite the rise in regulatory approvals, rigorous compliance mandates and protracted approval procedures present obstacles for new market entrants. The Fusion Biopsy Market has intricate clinical validation procedures, hindering product commercialization. Companies must manage changing rules, which can impede innovation and delay market entry. Organizations that strategically adhere to compliance requirements will be more equipped to navigate these challenges and foster continuous growth.

Geographical Dominance:

North America Leads the Fusion Biopsy Market with Advanced Healthcare Infrastructure

North America leads the Fusion Biopsy Market, propelled by advanced healthcare infrastructure, widespread acceptance of precision diagnostics, and increasing incidences of prostate cancer. The United States excels in robust research and development spending and advantageous reimbursement policies, facilitating industry growth. This supremacy draws international entities, promoting innovation and technical progress. As demand escalates, enterprises focusing on North America have a competitive advantage in revenue expansion.

Key Players

The “Global Fusion Biopsy Market” study report will provide a valuable insight with an emphasis on the global market.  The major players in the market are Eigen, Koninklijke Philips N.V., Hitachi Ltd., Focal Healthcare, MedCom, ESAOTE SPA, KOELIS, BK Medical Holding Company Inc., Biobot Surgical Pte Ltd, Exact Imaging, and UC-Care Medical Systems Ltd.

Fusion Biopsy Market Segment Analysis

Based on the research, Verified Market Research has segmented the market into Biopsy Route, Product, End User, and Geography.

Fusion Biopsy Market, by Biopsy RouteTransrectalTransperinealFusion Biopsy Market, by ProductEquipmentConsumablesFusion Biopsy Market, by End-UserHospitalsDiagnostic CentersAmbulatory Care CentersAcademic & Research LaboratoriesFusion Biopsy Market, by GeographyNorth AmericaU.SCanadaMexicoEuropeGermanyFranceU.KRest of EuropeAsia PacificChinaJapanIndiaRest of Asia PacificROWMiddle East & AfricaLatin America

Browse Related Reports:

Global Liquid Biopsy Market Size By Biomarker (Circulating Tumor Cells, Circulating Nucleic Acids), By Technology (NGS, PCR Microarrays), By Application (Cancer, Reproductive Health), End-User (Hospitals, Specialty Clinics), By Geography, And Forecast

Global Biopsy Devices Market Size By Product (Instruments For Needle-Based Biopsy, Biopsy Guidance Systems, Biopsy Needles (Disposable, Reusable), Biopsy Forceps), By End User (Hospitals & Clinics, Diagnostic Imaging Centres, Research Labs & Pharmaceutical Companies), By Application (Breast Biopsy, Bone Marrow Biopsy, Colorectal Biopsy, Lung Biopsies, Prostate Biopsies), By Geography, And Forecast

Global Plastic Surgery And Integumentary System Procedures Market Size By Procedure (Prefilled Syringe Biopsy, Excisional Biopsy), By Operating Area (Eyelids, Subcutaneous Tissue), By Application (Skin Grafts, Allograft), By End User (Hospitals And Clinics, Research Laboratories), By Geography, And Forecast

Global Biopsy Needles Market Size By Product Type (Biopsy Needles, Aspiration Needles), By Application (Tumor/Cancer Applications, Wound Applications), By Procedure (Image-guided Procedures, Non-image-guided Procedures), By End-User (Hospitals & Surgical Centers, Diagnostic Clinics & Pathology Laboratories, Ambulatory Care Centers, Research & Academic Institutes), By Geography, And Forecast

Top 7 Implantable Medical Device Companies advancing patient care

Visualize Fusion Biopsy Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research® stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, VMR has been instrumental in providing founders and companies with precise, up-to-date research data.

With a team of 500+ Analysts and subject matter experts, VMR leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.

VMR’s domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis cover over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.

Verified Market Research® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights VMR’s dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.

Contact Us
Mr. Edwyne Fernandes
Verified Market Research®
US: +1 (650)-781-4080
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/
Follow Us: LinkedIn | Twitter | Threads | Instagram | Facebook

Logo: https://mma.prnewswire.com/media/2015407/VMR_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fusion-biopsy-market-is-expected-to-generate-a-revenue-of-usd-1448-15-million-by-2032–globally-at-8-9-cagr-verified-market-research-302393044.html

Related Topics:
Continue Reading

Technology

IIFL Capital’s Maiden Late-Stage Private Equity Fund Announces First Close at ~ ₹500 Crore

Published

24 minutes ago

on

October 22, 2026

By

IIFL Capital’s Late-Stage Private Equity Fund targets a final close in excess of ₹1,000 crore within nine months from First CloseTwo transactions have already been committed with a pipeline of seven to eight deals under evaluation

MUMBAI, India, Oct. 22, 2026 /PRNewswire/ — IIFL Capital Asset Management Limited, the Asset Management arm of IIFL Capital, today announced that the IIFL Late-Stage Private Equity Fund, the maiden fund of its private equity platform, achieved its first close on 15 September 2026 with aggregate capital commitments of ~ ₹500 crore. The Fund invests in scaled-up, profitable Indian enterprises that are preparing to list on the public markets in the near term.

The Fund is targeting a total corpus of ₹1,000 crore, with a greenshoe option of additional ₹1,000 crore. It will remain open for subscription after the first close and aims to reach its final close within the next nine months. A larger corpus allows the Fund to back high-quality companies operating on a scale, in line with its late-stage, pre-IPO strategy.

The Fund is also evaluating a robust pipeline of opportunities, ranging from term sheet negotiations to transactions under diligence. The pipeline is diversified across integrated security-as-a-service, railway and wind energy components, specialty chemicals, defence equipment, IT-enabled services, pre-engineered buildings and consumer technology.

The Fund follows a clear mandate focused on scaled businesses nearing a public listing. The fund looks at sectors that envisage growth rate of 15%-18% per annum. The investee company should be amongst the top three-five players in its category, should have an EBITDA of at least ₹75-100 crore at investment with the intention to pursue IPO within three years. The average deal size is expected to be ₹50-100 crore per transaction.

Commenting on the milestone, Mr. Deepak Mittal, Chief Investment Officer and Head – Private Equity, IIFL Capital Asset Management Limited, said: “The first close marks the point at which this Fund moves from being a proposition to being a portfolio. We are grateful to our investors for their confidence in a volatile global environment. With two high-quality transactions already committed and a live pipeline of seven to eight opportunities, we believe IIFL’s capabilities give us a distinct advantage in backing scaled enterprises on their journey to the public markets.”

The first close comes in the backdrop of India’s primary market revival. After a subdued April-June quarter, July and August 2026 together saw 35 mainboard IPOs, and foreign portfolio investors returned as net buyers, including through IPOs. Real GDP grew 7.8% in Q1 FY27, with gross fixed capital formation up 11.9%, supporting the sectors the Fund is targeting.

About IIFL Capital Asset Management Limited

IIFL Capital Asset Management Limited (formerly IIFL Securities Alternate Asset Management Limited) is the Investment Manager for Alternative Investment Funds sponsored by IIFL Capital Services Limited. It is registered with SEBI as an Alternative Investment Fund manager (IN/AIF3/19-20/0770, IN/AIF2/21-22/088), Investment Adviser (INA000019956) and Portfolio Manager (INP000009445). Registered office: Ground Floor 01, Hubtown Solaris, Saiwadi, N S Phadke Road, Andheri East, Mumbai 400069. Website: assetmanagement.iiflcapital.com

About IIFL Capital Services Ltd

IIFL Capital Services Ltd (formerly known as IIFL Securities Limited) (NSE: IIFLCAPS) (BSE: 542773) is one of the key capital market players in the Indian financial services space. IIFL Capital offers broking services, wealth management, financial products distribution, institutional broking, research and investment banking services.

Disclaimer: This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any units of the IIFL Late-Stage Private Equity Fund or any securities. Investments in alternative investment funds are subject to market and other risks, including loss of capital. Investors should read the Private Placement Memorandum, including the risk factors, before investing. Registration granted by SEBI, enlistment with BSE, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Past performance of securities/instruments is not indicative of their future performance.

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/iifl-capitals-maiden-late-stage-private-equity-fund-announces-first-close-at–500-crore-302915550.html

Continue Reading

Technology

Snapmaker Introduces New Filament Bundle, Expanding Its Full Spectrum Printing Ecosystem

Published

24 minutes ago

on

October 22, 2026

By

The Snapmaker PLA Full Spectrum Filament Bundle (White Edition) combines pure-white capability, more saturated cyan, magenta, and yellow filaments, and finely tuned light-transmission properties for vibrant, natural-looking color mixes. It expands Snapmaker’s integrated ecosystem of dedicated materials, Snapmaker Orca software, and U1 hardware.

SHENZHEN, China, Oct. 22, 2026 /PRNewswire-PRWeb/ — Snapmaker has introduced the Snapmaker PLA Full Spectrum Filament Bundle (White Edition), expanding the creative possibilities of layered color mixing on Snapmaker U1. The four-spool set combines semi-translucent cyan, magenta, yellow, and white PLA filaments to produce a broader palette, from vivid color mixes and soft pastels to directly printed pure-white details.

“Together with the reformulated color filaments, the addition of white opens up a broader range of visual styles.” — Blayne Sapelli, Creative Marketing Manager at Snapmaker.

Four Filaments, Beyond Four Colors

Full Spectrum color mixing creates additional perceived colors by alternating thin layers of semi-translucent filaments along the Z-axis. As light interacts with these layers, their colors blend visually, allowing a single print to go beyond the four loaded filament colors.

Snapmaker Orca, Snapmaker’s official slicing software, supports this layered color mixing workflow. Together with U1’s multi-toolhead architecture, it provides a practical foundation for exploring more colors with a small set of materials.

Radu “Ratdoux,” creator of Full Spectrum and now part of the Snapmaker team, said: “Full Spectrum changes the way we think about color in consumer FDM printing. Instead of adding more and more individual filament colors, we can use a small set of calibrated materials together with software and multi-toolhead hardware to generate a much broader spectrum. Our goal is to make that process simple enough that users can focus on what they want to create rather than how to engineer the color.”

Filaments Engineered for Brighter Color

White filament brings two distinct benefits: it enables pure-white areas that layered color mixing alone cannot produce, and it brightens mixed colors while reducing saturation for lighter, softer tones. Reformulated cyan, magenta, and yellow filaments offer stronger saturation, helping deliver more vibrant mixes.

The filaments’ color and Transmission Distance properties are tuned to promote natural blending and help reduce visible horizontal stripes. On Snapmaker U1, RFID recognition automatically loads preset filament information, simplifying setup.

These properties give creators more flexibility to combine vivid accents, gentle shades, and white details in character models, collectibles, home décor, and sculptural artwork. The four-spool approach also reduces the need to store separate filament colors for occasional use.

“Adding white is a meaningful step for creators who want lighter palettes and pure-white details within the same four-spool setup,” said Blayne Sapelli, Creative Marketing Manager at Snapmaker, “Together with the reformulated color filaments, it opens up a different range of visual styles. It also reflects how we are building our ecosystem: developing dedicated materials around real creative needs and connecting them with the tools people use to print.”

An Integrated Ecosystem for Color Creation

The Snapmaker PLA Full Spectrum Filament Bundle (White Edition) joins the Snapmaker PLA Full Spectrum Filament Bundle (Gray Edition) and the SnapSpeed PLA CMYK Lithophane Filament Bundle, expanding Snapmaker’s official lineup to three purpose-designed bundles.

The two PLA Full Spectrum bundles are designed for three-dimensional color mixing. The new bundle enables brighter mixes, softer pastels, and pure-white details, while the Gray Edition offers darker, more muted tones. The CMYK Lithophane bundle is optimized for flat, layered-color printing, including colorful backlit lithophanes made from photographs and illustrations.

Built around U1 and Snapmaker Orca, the lineup connects specialized materials with hardware and software support.

Pricing and Product Information

The bundle is priced at US$89 and contains four 1 kg spools, totaling 4 kg. For product details and regional purchasing information, visit the official product page.

About Snapmaker

Snapmaker makes products that empower everyone to change the world — literally. From 3-in-1 desktop fabrication machines to the Snapmaker U1 multicolor, multimaterial, toolchanger 3D printer, to the software that powers it all, Snapmaker is building an ecosystem that democratizes creation. Snapmaker: Make Something Wonderful.

For more information, visit Snapmaker.com.

Media Contact

Hao Jiang, Snapmaker, 86 13588745216, jianghao@snapmaker.com, www.snapmaker.com

View original content to download multimedia:https://www.prweb.com/releases/snapmaker-introduces-new-filament-bundle-expanding-its-full-spectrum-printing-ecosystem-302915783.html

SOURCE Snapmaker

Continue Reading

Technology

Today, Intelligent Legal Solutions (ILS) and Anduin announced a partnership to provide a more streamlined service for both fund managers and law firms

Published

24 minutes ago

on

October 22, 2026

By

PALO ALTO, Calif., Oct. 22, 2026 /PRNewswire/ — Intelligent Legal Solutions (ILS) and Anduin have announced a partnership to create a more connected fundraising experience for private markets fund managers and law firms.

ILS is the legal technology company behind ProVision, a platform for private investment funds lawyers and their clients, while Anduin provides technology for private markets fundraising and investor operations. Through the partnership, the companies will build an integration connecting their platforms to support a more streamlined, end-to-end fundraising process.

Launched in 2024, ILS works with 89% of law firms ranked in the top three bands by Chambers USA for Private Equity: Fund Formation nationwide. Its technology has supported fundraises totaling more than $825 billion across North America, the UK, EMEA and APAC.

Anduin’s platform has supported more than 1,300 private investment funds, onboarded over 76,000 investors and powered more than $265 billion in capital raised. Its customers represent more than $7 trillion in aggregate assets under management.

Fergus Plant, Co-Founder of ILS, said: “We are hugely excited to announce our partnership with Anduin. They are a mainstay of the private markets tech space, and we are proud to collaborate to bring a more complete solution to our customers. Our recent launch of the Fund Manager Portal for ProVision more closely aligns our customers, deepening the benefits of this relationship.”

Eliot Hodges, CEO of Anduin, said: “Fundraising still involves too many handoffs between systems, teams and advisers. By connecting Anduin’s subscription and investor onboarding workflows with ProVision’s side letter, comment memo, MFN and obligation management capabilities, we can help firms carry data more seamlessly through the fundraising process and reduce the operational burden around close.”

Read more at https://anduintransact.com/blog/anduin-partners-with-ils 

Fund managers and law firms interested in learning more can contact:

About Anduin
Anduin is the leading digital platform for managing fund lifecycles and LP relationships. The company has facilitated $118 billion in global capital and supports 48,000+ investors across 890+ funds. Learn more at anduintransact.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/today-intelligent-legal-solutions-ils-and-anduin-announced-a-partnership-to-provide-a-more-streamlined-service-for-both-fund-managers-and-law-firms-302916435.html

SOURCE Anduin Transactions

Continue Reading

Trending